Why the UK medicine supply chain is dangerously exposed to global shocks

**Lead**

The United Kingdom’s medicine supply chain is facing unprecedented scrutiny as repeated global crises expose its dangerous fragility. From the Covid-19 pandemic to geopolitical tensions in Eastern Europe and extreme weather events in Asia, the UK now imports more than half of its medicines and the vast majority of active pharmaceutical ingredients (APIs). This dependency has left the National Health Service (NHS) vulnerable to supply interruptions that could jeopardise patient care and national security, according to experts and parliamentary reports.

**Context**

The problem is not new but has been systematically underestimated. Over the past two decades, the UK pharmaceutical industry has shifted production abroad, driven by lower costs and less stringent environmental regulations. Today, approximately 80 per cent of APIs used in British medicines come from China and India. Finished medicines, including antibiotics, painkillers, and cancer treatments, are often sourced from multiple countries via complex just-in-time logistics. The Department of Health and Social Care acknowledges that around 45 per cent of medicines used in the NHS are imported, with some critical products having only a single source of supply.

Recent shocks have tested the system severely. The Covid-19 pandemic triggered global export restrictions and panic buying, leaving UK hospitals scrambling for essential drugs. More recently, Russia’s invasion of Ukraine disrupted supplies of key gases used in anaesthesia and surgical procedures. Flooding in India and China has intermittently closed factories producing basic painkillers. In 2022, a heatwave in France forced the shutdown of a major pharmaceutical plant, affecting supplies of certain injectable drugs. Each time, the NHS has relied on short-term measures such as stockpiling, substitution, and import authorisations, but these are not sustainable solutions.

Parliamentary inquiries have repeatedly highlighted the lack of resilience. The House of Commons Health and Social Care Committee warned in 2023 that the UK’s approach to medicine supply was “reactive rather than strategic”. The National Audit Office found that the Department of Health and Social Care lacks visibility over the full supply chain, making it difficult to anticipate and mitigate risks. Meanwhile, Brexit has introduced additional customs and regulatory barriers, slowing the movement of medicines between Great Britain and Northern Ireland, and between the UK and EU member states.

**Analise**

The implications of this vulnerability extend far beyond occasional shortages. For patients, a disrupted supply chain can mean delayed treatments, alternative medications with different side effects, or in extreme cases, cancelled surgeries. For the NHS, it creates operational inefficiencies and financial strain, as staff must scramble to find replacements and manage increased drug prices. For the UK government, it represents a threat to public health security and a potential source of political instability if the public loses confidence in the healthcare system.

Internationally, the UK is not alone in facing these challenges. The United States, European Union, and other developed nations have all launched initiatives to reshore manufacturing and diversify sources. The EU’s Critical Medicines Act, proposed in 2024, aims to strengthen supply chains for essential drugs. However, the UK’s departure from the EU has made it more difficult to coordinate such efforts and has reduced its bargaining power in global pharmaceutical markets.

There is also a growing recognition that the current model is unsustainable for the long term. The reliance on a handful of low-cost suppliers creates a moral hazard: the true cost of resilience is externalised onto patients and taxpayers when disruptions occur. Calls are mounting for a national strategy that includes financial incentives for domestic production, strategic stockpiling of critical medicines, and greater transparency across the entire supply chain. Some economists argue that the NHS should be allowed to pay a premium for security of supply, treating it as an insurance policy against future shocks.

**Fontes**

This article is based on publicly available information from the House of Commons Health and Social Care Committee report on medicine supply chains (2023), the National Audit Office’s report on managing the supply of medicines (2022), data from the Department of Health and Social Care, and analyses published by the King’s Fund and the Nuffield Trust. International comparisons draw on reports from the European Commission and the U.S. Food and Drug Administration.